In conclusion, GPR has better diagnostic efficacy than APRI, FIB-4, and AST/ALT for the staging of liver fibrosis in patients with CHB, the predictive value of GPR for HBeAg positivity is better than that for HBeAg negativity, and GPR is a better alternative to liver tissue biopsy. This evidence concerns the gene ALDH18A1 and Hepatic fibrosis.